Merus (MRUS) Competitors $94.86 -0.03 (-0.03%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MRUS vs. BNTX, TEVA, GMAB, SMMT, ASND, VTRS, RDY, MRNA, ROIV, and QGENShould you be buying Merus stock or one of its competitors? The main competitors of Merus include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Roivant Sciences (ROIV), and QIAGEN (QGEN). These companies are all part of the "pharmaceutical products" industry. Merus vs. Its Competitors BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Moderna Roivant Sciences QIAGEN BioNTech (NASDAQ:BNTX) and Merus (NASDAQ:MRUS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations. Do analysts recommend BNTX or MRUS? BioNTech currently has a consensus target price of $134.32, suggesting a potential upside of 27.85%. Merus has a consensus target price of $93.12, suggesting a potential downside of 1.83%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNTech 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.64Merus 1 Sell rating(s) 14 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.16 Which has more volatility and risk, BNTX or MRUS? BioNTech has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, Merus has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Which has better earnings & valuation, BNTX or MRUS? Merus has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioNTech$2.98B8.48-$719.92M-$1.60-65.66Merus$36.13M198.56-$215.33M-$5.50-17.25 Is BNTX or MRUS more profitable? BioNTech has a net margin of -12.20% compared to Merus' net margin of -685.64%. BioNTech's return on equity of -1.84% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets BioNTech-12.20% -1.84% -1.59% Merus -685.64%-50.28%-42.00% Do institutionals & insiders have more ownership in BNTX or MRUS? 15.5% of BioNTech shares are owned by institutional investors. Comparatively, 96.1% of Merus shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 3.7% of Merus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to BNTX or MRUS? In the previous week, Merus had 5 more articles in the media than BioNTech. MarketBeat recorded 10 mentions for Merus and 5 mentions for BioNTech. BioNTech's average media sentiment score of 0.44 beat Merus' score of -0.04 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Merus 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral SummaryBioNTech beats Merus on 11 of the 16 factors compared between the two stocks. Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRUS vs. The Competition Export to ExcelMetricMerusMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.17B$3.41B$6.08B$10.51BDividend YieldN/A2.29%5.73%4.78%P/E Ratio-17.2522.5084.1027.01Price / Sales198.56481.27607.14130.56Price / CashN/A46.9737.8662.13Price / Book10.0310.4112.236.56Net Income-$215.33M-$52.47M$3.32B$276.88M7 Day Performance0.51%1.72%0.46%0.68%1 Month Performance39.12%13.86%7.73%3.86%1 Year Performance83.33%12.07%70.73%34.96% Merus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRUSMerus1.5876 of 5 stars$94.860.0%$93.12-1.8%+81.4%$7.17B$36.13M-17.2537Short Interest ↓BNTXBioNTech2.4505 of 5 stars$105.16-0.3%$134.56+28.0%-10.8%$25.36B$2.98B-65.726,772Analyst ForecastTEVATeva Pharmaceutical Industries3.4055 of 5 stars$19.99-0.1%$25.57+27.9%+8.8%$22.95B$16.54B-124.9436,830Positive NewsGMABGenmab A/S3.7015 of 5 stars$33.31-0.7%$40.80+22.5%+44.9%$21.55B$3.12B19.632,682Trending NewsAnalyst ForecastShort Interest ↑Analyst RevisionHigh Trading VolumeSMMTSummit Therapeutics3.0143 of 5 stars$22.15+3.4%$31.29+41.2%-6.4%$15.92B$700K-21.93110Upcoming EarningsGap DownASNDAscendis Pharma A/S2.8921 of 5 stars$210.83+3.3%$244.36+15.9%+58.9%$12.59B$393.54M-40.861,017News CoverageAnalyst ForecastAnalyst RevisionHigh Trading VolumeVTRSViatris3.0766 of 5 stars$10.13-0.6%$10.40+2.7%-14.6%$11.88B$14.74B-3.4932,000News CoverageAnalyst ForecastRDYDr. Reddy's Laboratories3.042 of 5 stars$14.12-0.3%$16.95+20.0%-10.1%$11.82B$3.81B21.3927,811MRNAModerna4.251 of 5 stars$27.54-3.3%$41.81+51.8%-52.8%$11.08B$3.24B0.005,800Analyst RevisionGap DownROIVRoivant Sciences3.1071 of 5 stars$16.26+0.6%$19.94+22.6%+42.9%$11.04B$29.05M0.00860Insider TradeQGENQIAGEN4.1228 of 5 stars$46.99+0.4%$49.40+5.1%+14.5%$10.40B$1.98B27.765,765 Related Companies and Tools Related Companies BioNTech Competitors Teva Pharmaceutical Industries Competitors Genmab A/S Competitors Summit Therapeutics Competitors Ascendis Pharma A/S Competitors Viatris Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Roivant Sciences Competitors QIAGEN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRUS) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
